Growing Market Presence Scanwell Health’s recent collaboration with BD to develop at-home rapid SARS-CoV-2 tests demonstrates a strong position in infectious disease diagnostics, opening opportunities to partner with healthcare providers, pharmacies, and health systems seeking reliable point-of-care testing solutions.

Innovative Technology Adoption The company's use of computer vision, machine learning, and smartphone integration provides a scalable platform that can be expanded to additional diagnostic tests, appealing to organizations looking to modernize at-home testing and remote patient monitoring.

Market Expansion Potential With funding of 3.6 million dollars and a focus on infectious diseases like COVID-19 and influenza, Scanwell Health has the potential to target a wide array of health conditions, making it attractive for investors and health insurers aiming to reduce costs through early detection and remote diagnosis.

Strategic Acquisitions As part of BD, Scanwell Health gains access to a large customer base and distribution network, offering sales opportunities across a global healthcare market interested in digital health solutions that complement traditional diagnostics.

Small but Agile Despite a small team of 2-10 employees and revenue under one million dollars, Scanwell’s agile and innovative approach positions it well for rapid product development and partnerships with larger entities seeking to integrate digital diagnostics into existing healthcare workflows.